Compare Eli Lilly And Co (LLY) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ryanair Holdings plc — how do they compare? Eli Lilly And Co trades at $1,221.88 (market cap $1.08T), while Ryanair Holdings plc trades at $59.39 (market cap $29.63B). The key difference: Eli Lilly And Co is far larger — about 36.4× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| LLY | RYAAY | |
|---|---|---|
Market Cap | $1.08T | $29.63B |
Sector | Health | Industrials |
52-Week High | $1.24K | $73.82 |
52-Week Low | $639.43 | $53.24 |
Enterprise Value | $1.13T | $26.61B |
Dividend Yield | 0.57% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Ryanair Holdings (RYAAY) trades at $59.41, down 0.17% with bearish technical signals despite reasonable valuations (P/E 14.37). The airline reported mixed quarterly results with Q1 2026 beating expectations but Q2 2026 missing, while maintaining strong profitability (22.41% ROE) and a solid balance sheet with $3.96B cash. Recent news highlights operational challenges from lower fares and fuel costs, alongside strategic AI partnerships.
Outlook remains cautious due to near-term headwinds from fare pressure and geopolitical risks, but long-term prospects are supported by industry consolidation potential and strong financials. Analyst consensus is bullish (62.5% Buy ratings), viewing current weakness as overdone. Key risks include fuel price volatility and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
